Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.

Overview of attention for article published in Annals of Internal Medicine, December 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 5 news outlets
twitter: 9 X users
facebook: 1 Facebook page

reddit: 1 Redditor
bluesky: 5 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 10 Mendeley

So far, Altmetric has seen 5 Bluesky posts from 5 Bluesky users, with an upper bound of 37,307 followers.

RP @josephmarcusid.medsky.social: A phase 2 open label RCT of weekly Islatravir + Lenacapravir in patients living with HIV combared B/F/TAF: -Similar rate of viral suppression (VL

RP @scooper-id.bsky.social: Once-Weekly Oral Islatravir + Lenacapavir Maintains High Rates Of Virologic Suppression In Patients With HIV, (Study) #IDSky #MedSky www.acpjournals.org/doi/10.7326/...

Once-Weekly Oral Islatravir + Lenacapavir Maintains High Rates Of Virologic Suppression In Patients With HIV, (Study) #IDSky #MedSky www.acpjournals.org/doi/10.7326/...

RP @josephmarcusid.medsky.social: A phase 2 open label RCT of weekly Islatravir + Lenacapravir in patients living with HIV combared B/F/TAF: -Similar rate of viral suppression (VL

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 1 additional Bluesky posts.